Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer

Cancer Letters

Volumn 307, Issue 2, 2011, Pages 149-157

  Oshima, Kazuteru ^a   Naoi, Yasuto ^a   Kishi, Kazuki ^b   Nakamura, Yukiko ^a   Iwamoto, Takashi ^a   Shimazu, Kenzo ^a   Nakayama, Takahiro ^a   Kim, Seung Jin ^a   Baba, Yosuke ^b   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

Breast cancer; Chemotherapy; Gene expression signature; Mutation status; TP53

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TP53 GENE; WILD TYPE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLUSTER ANALYSIS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; PACLITAXEL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957645965     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.027     Document Type: Article

References (31)

1. Beriwal S., Schwartz G.F., Komarnicky L., Garcia-Young J.A. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J. 2006, 12:159-164.
2. Charfare H., Limongelli S., Purushotham A.D. Neoadjuvant chemotherapy in breast cancer. Brit. J. Surg. 2005, 92:14-23.
3. Sachelarie I., Grossbard M.L., Chadha M., Feldman S., Ghesani M., Blum R.H. Primary systemic therapy of breast cancer. Oncologist 2006, 11:574-589.
4. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., Theriault R.L., Singh G., Binkley S.M., Sneige N., Buchholz T.A., Ross M.I., McNeese M.D., Buzdar A.U., Hortobagyi G.N., Singletary S.E. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 1999, 17:460-469.
5. Bear H.D., Anderson S., Smith R.E., Geyer C.E., Mamounas E.P., Fisher B., Brown A.M., Robidoux A., Margolese R., Kahlenberg M.S., Paik S., Soran A., Wickerham D.L., Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 2006, 24:2019-2027.
6. Ko L.J., Prives C. P53: puzzle and paradigm. Genes Dev. 1996, 10:1054-1072.
7. Gasco M., Shami S., Crook T. The p53 pathway in breast cancer. Breast Cancer Res. 2002, 4:70-76.
8. Bertheau P., Espie M., Turpin E., Lehmann J., Plassa L.F., Varna M., Janin A., de The H. TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008, 75:132-139.
9. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace A.J., Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57:4285-4300.
10. Kandioler-Eckersberger D., Ludwig C., Rudas M., Kappel S., Janschek E., Wenzel C., Schlagbauer-Wadl H., Mittlbock M., Gnant M., Steger G., Jakesz R. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 2000, 6:50-56.
11. Chrisanthar R., Knappskog S., Lokkevik E., Anker G., Ostenstad B., Lundgren S., Berge E.O., Risberg T., Mjaaland I., Maehle L., Engebretsen L.F., Lillehaug J.R., Lonning P.E. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008, 3:e3062.
12. Geisler S., Lonning P.E., Aas T., Johnsen H., Fluge O., Haugen D.F., Lillehaug J.R., Akslen L.A., Borresen-Dale A.L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001, 61:2505-2512.
13. Bertheau P., Turpin E., Rickman D.S., Espie M., de Reynies A., Feugeas J.P., Plassa L.F., Soliman H., Varna M., de Roquancourt A., Lehmann-Che J., Beuzard Y., Marty M., Misset J.L., Janin A., de The H. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med. 2007, 4:e90.
14. Mieog J.S., van der Hage J.A., van de Vijuer M.J., van de Velde C.J. Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. Eur. J. Cancer 2006, 42:1369-1379.
15. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Brit. J. Cancer 2003, 88:406-412.
16. Soussi T. P53 alterations in human cancer: more questions than answers. Oncogene 2007, 26:2145-2156.
17. Righetti S.C., Della Torre G., Pilotti S., Menard S., Ottone F., Colnaghi M.I., Pierotti M.A., Lavarino C., Cornarotti M., Oriana S., Bohm S., Bresciani G.L., Spatti G., Zunino F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996, 56:689-693.
18. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999, 104:263-269.
19. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102:13550-13555.
20. Takahashi S., Moriya T., Ishida T., Shibata H., Sasano H., Ohuchi N., Ishioka C. Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci. 2008, 99:324-332.
21. Kim S.J., Taguchi T., Shimazu K., Tanji Y., Tamaki Y., Noguchi S. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide. Oncology 2009, 77:134-139.
22. Tanei T., Morimoto K., Shimazu K., Kim S.J., Tanji Y., Taguchi T., Tamaki Y., Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15:4234-4241.
23. Shimomura A., Miyoshi Y., Taguchi T., Tamaki Y., Noguchi S. Association of loss of BRCA1 expression with centrosome aberration in human breast cancer. J. Cancer Res. Clin. Oncol. 2009, 135:421-430.
24. Bloom H.J., Richardson W.W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Brit. J. Cancer 1957, 11:359-377.
25. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100:8418-8423.
26. Olivier M., Langerod A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Bieche I., Varley J., Bignon Y., Uhrhammer N., Winqvist R., Jukkola-Vuorinen A., Niederacher D., Kato S., Ishioka C., Hainaut P., Borresen-Dale A.L. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin. Cancer Res. 2006, 12:1157-1167.
27. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
28. Langerod A., Zhao H., Borgan O., Nesland J.M., Bukholm I.R., Ikdahl T., Karesen R., Borresen-Dale A.L., Jeffrey S.S. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007, 9:R30.
29. Kakudo Y., Shibata H., Otsuka K., Kato S., Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res. 2005, 65:2108-2114.
30. Abdel-Fatah T.M., Powe D.G., Agboola J., Adamowicz-Brice M., Blamey R.W., Lopez-Garcia M.A., Green A.R., Reis-Filho J.S., Ellis I.O. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J. Pathol. 2010, 220:419-434.
31. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 2002, 19:607-614.